{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:16:23Z","timestamp":1792440983710,"version":"4.5.0"},"reference-count":42,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Guidelines regarding long-term use with onabotulinumtoxinA (onaBT-A) in chronic migraine (CM) prophylaxis are lacking. This multicentric prospective real-life study aimed to assess the efficacy and safety of a long-term treatment. A total of 195 chronic migraine patients were treated with onaBT-A, every 3 months for 5 cycles (Phase 1). In the Phase 2 of the study, depending on response rate, patients were divided into \u201cresponders\u201d (R), \u201cpartially responders\u201d (PR) and \u201cnon-responders\u201d (NR). Then, we proposed to R and PR patients to continue with an additional 12 months of treatment (additional 4 sessions). Response to treatment and adverse events were collected for the entire duration of the study. Of the 195 patients included (females 82.1%, mean age 47.4 \u00b1 12.4), at the end of Phase 1 there were 52.3% of R patients, 17.9% of PR patients, 15.4% of NR patients and 14.4% drop-outs. During Phase 2 of treatment, R patients presented a maintenance of the improvement achieved during the first year of treatment, as well as PR patients. Except for three serious adverse events not related to treatment, all other adverse events were mild or moderate in severity and resolved without sequelae. In the literature, adherence to oral migraine-preventive medications among patients with CM was found to be less than 25%. The results of this prospective real-life multicenter study show efficacy, safety and adherence to a long-term treatment with onaBT-A.<\/jats:p>","DOI":"10.3390\/toxins15010034","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T03:00:59Z","timestamp":1672628459000},"page":"34","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Ilenia","family":"Corbelli","sequence":"first","affiliation":[{"name":"Neurological Clinic, S. Maria Misericordia Hospital, Department of Medicine, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Verzina","sequence":"additional","affiliation":[{"name":"Neurological Clinic, S. Maria Misericordia Hospital, Department of Medicine, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1422-0237","authenticated-orcid":false,"given":"Ilaria","family":"Leone De Magistris","sequence":"additional","affiliation":[{"name":"Neurological Clinic, S. Maria Misericordia Hospital, Department of Medicine, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"De Vanna","sequence":"additional","affiliation":[{"name":"Neurological Clinic, S. Maria Misericordia Hospital, Department of Medicine, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0715-6396","authenticated-orcid":false,"given":"Paolo","family":"Eusebi","sequence":"additional","affiliation":[{"name":"Neurological Clinic, S. Maria Misericordia Hospital, Department of Medicine, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Mataluni","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Systems Medicine, University of Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-594X","authenticated-orcid":false,"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Systems Medicine, University of Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9259-8158","authenticated-orcid":false,"given":"Addolorata Maria Pia","family":"Prudenzano","sequence":"additional","affiliation":[{"name":"Headache Center, Neurological Clinic \u201cL. Amaducci\u201d, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Trojano","sequence":"additional","affiliation":[{"name":"Headache Center, Neurological Clinic \u201cL. Amaducci\u201d, Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5888-3024","authenticated-orcid":false,"given":"Marianna","family":"Delussi","sequence":"additional","affiliation":[{"name":"Applied Neurophysiology and Pain (ANP) Unit, University of Bari Aldo Moro, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6567-5373","authenticated-orcid":false,"given":"Marina","family":"De Tommaso","sequence":"additional","affiliation":[{"name":"Applied Neurophysiology and Pain (ANP) Unit, University of Bari Aldo Moro, 70121 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Silvestro","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioacchino","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[{"name":"The Institute of Neurology, Agostino Gemelli University Policlinic IRCCS, 00168 Rome, Italy"},{"name":"Department of Neurosciences, Catholic University of the Sacred Heart, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sarchielli","sequence":"additional","affiliation":[{"name":"Neurological Clinic, S. Maria Misericordia Hospital, Department of Medicine, University of Perugia, 06129 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The international classification of headache disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0333102414552532","article-title":"The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results","volume":"35","author":"Adams","year":"2015","journal-title":"Cephalalgia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","article-title":"Medication-overuse headache: Risk factors, pathophysiology and management","volume":"12","author":"Diener","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/head.12505_2","article-title":"Episodic and chronic migraine headache: Breaking down barriers to optimal treatment and prevention","volume":"55","author":"Lipton","year":"2015","journal-title":"Headache"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1468-1331.2011.03497.x","article-title":"Treatment of medication overuse headache-guideline of the EFNS headache panel","volume":"18","author":"Evers","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"g1416","DOI":"10.1136\/bmj.g1416","article-title":"Chronic migraine","volume":"348","author":"Schwedt","year":"2014","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalalgia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.amjmed.2020.01.031","article-title":"Medications Approved for Preventing Migraine Headaches","volume":"133","author":"Spindler","year":"2020","journal-title":"Am. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"Onabotulinumtoxin a for treatment of chronic migraine: Results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"Onabotulinumtoxin a for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_11","first-page":"CD011616","article-title":"Botulinum toxins for the prevention of migraine in adults","volume":"25","author":"Herd","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of Onabotulinumtoxin a for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J. Headache Pain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","article-title":"An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: The REPOSE study","volume":"20","author":"Ahmed","year":"2019","journal-title":"J. Headache Pain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1069-e83","DOI":"10.1111\/ene.13657","article-title":"Prospective real-world analysis of OnabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal","volume":"25","author":"Andreou","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10072-018-3391-5","article-title":"OnabotulinumtoxinA in chronic migraine: Long-term efficacy in a prophylactic medication free cohort","volume":"39","author":"Pari","year":"2018","journal-title":"Neurol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s10194-018-0918-3","article-title":"Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment","volume":"19","author":"Vikelis","year":"2018","journal-title":"J. Headache Pain."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000499764","article-title":"Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study","volume":"81","author":"Brighina","year":"2019","journal-title":"Eur. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s10072-020-04283-y","article-title":"Chronic migraine long-term regular treatment with onabotulinumtoxinA: A retrospective real-life observational study up to 4 years of therapy","volume":"41","author":"Santoro","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ane.13600","article-title":"Long-term adherence, safety, and efficacy of repeated onabotulinumtoxinA over five years in chronic migraine prophylaxis","volume":"145","author":"Argyriou","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1017\/cjn.2021.153","article-title":"OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study","volume":"49","author":"Boudreau","year":"2022","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_21","first-page":"22","article-title":"Systematic review of migraine prophylaxis adherence and persistence","volume":"20","author":"Hepp","year":"2014","journal-title":"J. Manag. Care Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/j.1526-4610.2011.01986.x","article-title":"Tolerance and loss of beneficial effect during migraine prophylaxis: Clinical considerations","volume":"51","author":"Loder","year":"2011","journal-title":"Headache"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/0333102414547138","article-title":"Adherence to oral migraine-preventive medications among patients with chronic migraine","volume":"35","author":"Hepp","year":"2015","journal-title":"Cephalalgia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","article-title":"A Double-Blind Comparison of OnabotulinumtoxinA (BOTOX) and Topiramate (TOPAMAX) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study","volume":"49","author":"Mathew","year":"2009","journal-title":"Headache"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11916-019-0768-y","article-title":"CGRP Antagonists for the Treatment of Chronic Migraines: A Comprehensive Review","volume":"23","author":"Urits","year":"2019","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"671845","DOI":"10.3389\/fphar.2021.671845","article-title":"Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT","volume":"86","author":"Silberstein","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","article-title":"The 2012 AHS\/AAN guidelines for prevention of episodic migraine: A summary and comparison with other recent clinical practice guidelines","volume":"52","author":"Loder","year":"2012","journal-title":"Headache"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3389\/fneur.2017.00655","article-title":"Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine","volume":"8","author":"Sarchielli","year":"2017","journal-title":"Front. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0333102414561873","article-title":"Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?","volume":"35","author":"Larrosa","year":"2015","journal-title":"Cephalalgia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00702-016-1539-0","article-title":"Long-term treatment of chronic migraine with Onabotulinumtoxin A: Efficacy, quality of life and tolerability in a real-life setting","volume":"123","author":"Kollewe","year":"2016","journal-title":"J. Neural. Transm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s10194-016-0634-9","article-title":"Increased efficacy of regularly repeated cycles with Onabotulinumtoxin A in MOH patients beyond the first year of treatment","volume":"17","author":"Guerzoni","year":"2016","journal-title":"J. Headache Pain"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-016-0591-3","article-title":"A two years open-label prospective study of Onabotulinumtoxin A 195U in medication overuse headache: A real-world experience","volume":"17","author":"Negro","year":"2015","journal-title":"J. Headache Pain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1007\/s10072-017-2884-y","article-title":"Action mechanisms of Onabotulinumtoxin-A: Hints for selection of eligible patients","volume":"38","author":"Lovati","year":"2017","journal-title":"Neurol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Santoro, A., Delussi, M., Leone, M., Miscio, A.M., De Rocco, L., Leo, G., and De Tommaso, M. (2019). Effects of Botulinum Toxin on Migraine Attack Features in Chronic Migraine: A Six-Month Open-Label Observation Study through Electronic Diary Smartphone Application. Toxins, 11.","DOI":"10.3390\/toxins11110668"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.pain.2010.09.030","article-title":"Central sensitization: Implications for the diagnosis and treatment of pain","volume":"152","author":"Woolf","year":"2011","journal-title":"Pain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1129-2377-15-54","article-title":"Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.","volume":"15","author":"Khalil","year":"2014","journal-title":"J. Headache Pain"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1468-2982.2008.01555.x","article-title":"Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults","volume":"28","author":"Silberstein","year":"2008","journal-title":"Cephalalgia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/ene.12393","article-title":"Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine","volume":"21","author":"Diener","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_42","unstructured":"R Core Team (2021, November 11). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. Available online: http:\/\/www.R-project.org\/."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/1\/34\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:49:21Z","timestamp":1760147361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/15\/1\/34"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["toxins15010034"],"URL":"https:\/\/doi.org\/10.3390\/toxins15010034","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]}}}